Clinical Trials on Liver Cirrhosis, Biliary

Total 15222 results

University Health Network, Toronto

Unknown

Family Studies in Primary Biliary Cirrhosis (PBC)

Biliary Cirrhosis, Primary

Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
CymaBay Therapeutics, Inc.

Terminated

Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis (PBC)

Germany, United States, Canada, United Kingdom, Poland
University Health Network, Toronto

Unknown

Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary | Biliary Cirrhosis, Primary

Canada
Xijing Hospital of Digestive Diseases

Unknown

Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis

Primary Biliary Cirrhosis

China
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cirrhosis

China
Christopher Bowlus, MD
Bristol-Myers Squibb

Completed

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Dr. Falk Pharma GmbH

Terminated

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

France, Germany
University of California, Davis
Genentech, Inc.

Completed

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
George Brewer
FDA Office of Orphan Products Development

Completed

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
Janssen Research & Development, LLC

Completed

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cirrhosis

United States, Canada
University of Alberta
Canadian Institutes of Health Research (CIHR); Gilead Sciences; Abbott

Completed

Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (HAART)

Primary Biliary Cirrhosis

Canada
Beijing 302 Hospital

Unknown

Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
Beijing Friendship Hospital
Beijing Trendful Kangjian Medical Information Consulting Limited Company

Completed

Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
Richard Burt, MD
Northwestern Memorial Hospital

Withdrawn

Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis
Robert Chunhua Zhao, MD, PhD
Peking Union Medical College Hospital

Unknown

Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis (MSCsTreatPBC)

Primary Biliary Cirrhosis

China
National Center for Research Resources (NCRR)
Tufts Medical Center

Completed

Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis

Liver Cirrhosis, Biliary
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Dr. Falk Pharma GmbH

Completed

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Germany
Instituto Nacional de Ciencias Medicas y Nutricion...

Unknown

Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders

Primary Biliary Cirrhosis

Mexico
University of Florida
Shionogi Inc.; The PBCers Organization

Completed

Use of Fenofibrate for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Benedetta Terziroli, MD
Intercept Pharmaceuticals; Vifor Pharma; Fondazione Epatocentro Ticino

Completed

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

Primary Biliary Cirrhosis

Switzerland
University of Miami
Mayo Clinic

Withdrawn

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
The Cleveland Clinic

Completed

Pentoxifylline for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Mayo Clinic

Active, not recruiting

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals

Completed

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
Xijing Hospital of Digestive Diseases

Unknown

Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
Fast Forward Pharmaceuticals

Unknown

Pilot Study of FFP104 Dose Escalation in PBC Subjects

Primary Biliary Cirrhosis

Netherlands, United Kingdom
Instituto Nacional de Ciencias Medicas y Nutricion...

Completed

High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Mexico
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
Mayo Clinic
UCB Pharma

Completed

Moexipril for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Liver Cirrhosis, Biliary

United States, Puerto Rico
National Scientific Medical Center, Kazakhstan
Eurasia Invest Ltd.; Ministry of Education and Science, Republic of Kazakhstan

Completed

Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis

Primary Biliary Cirrhosis

Kazakhstan
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle University; National Institute for Health Research, United Kingdom; Department of Health, United Kingdom

Completed

B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis (RITPBC)

Fatigue | Primary Biliary Cirrhosis

United Kingdom
Mayo Clinic
American College of Gastroenterology

Completed

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) (PBC)

Fatigue | Primary Biliary Cirrhosis

United States
University of Alberta
GlaxoSmithKline; Axcan Pharma

Completed

Study of Combivir for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Canada, United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)

Primary Biliary Cirrhosis | PBC

United States, United Kingdom, Canada
University of Sao Paulo General Hospital

Completed

Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine

Primary Biliary Cirrhosis | Ursodeoxycholic Acid

Brazil
University of Aarhus
Aarhus University Hospital; Hvidovre University Hospital

Recruiting

Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

Denmark
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

United States, Korea, Republic of, Belgium, Spain, France, Switzerland, Romania, United Kingdom, Austria, Israel, Australia, Argentina, Canada, Chile, Germany, Greece, Hungary, Italy, Mexico, Netherlands, Poland, Czechia, New Zealand, Turke... and more
Target PharmaSolutions, Inc.

Active, not recruiting

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

Biliary Cirrhosis, Primary

United States
Ipsen

Active, not recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Primary Biliary Cirrhosis

United States, France, Spain, Belgium, Germany, Switzerland, Brazil, United Kingdom, Argentina, Canada, Chile, Italy, South Africa, Turkey
Instituto Mexicano del Seguro Social

Active, not recruiting

A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis

Primary Biliary Cirrhosis

Mexico
Sahlgrenska University Hospital, Sweden
Albireo

Terminated

IBAT Inhibitor A4250 for Cholestatic Pruritus

Biliary Cirrhosis, Primary

Sweden

Clinical Trials on Liver Cirrhosis, Biliary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations